SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

(Reuters) - U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk (NYSE: NVO )'s highly in-demand drugs for diabetes and weight loss, according to a review of patient data ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem ...

The stock is now heading for an eye-popping annual gain of over ... First, let's consider some background on this specific ...

Novo Nordisk (NVO) has released an update. Novo Nordisk announced that its board members and executives have sold a significant volume of ...

Novo Nordisk (NVO) has released an update. Novo Nordisk, a leading global healthcare company, recently reported that its board members and ...

I think the picture is murky after this, although overall Novo Nordisk maybe, even though the stock is down a little bit this year, maybe those numbers reassured investors a little bit about the near ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...

Danish drugmaker Novo Nordisk's shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as ...